Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SBRX17
- Development stage
- Preclinical
- Lead developer
- Stramsen Biotech
- Modality
- Small Molecules
01
Overview
SBRX17 is a plant-based drug candidate being developed by Stramsen Biotech for the management of dysmenorrhea (painful menstrual cramps). It is part of the company's SBRX series of therapeutics, which are derived from a proprietary database of several thousand medicinal plants. Stramsen Biotech, a Texas-based biopharmaceutical company, focuses on leveraging natural compounds to develop new drug therapies. SBRX17 is one of several candidates in the company's pipeline positioned for clinical trial advancement, although its specific molecular targets and active botanical ingredients remain proprietary and have not been publicly disclosed.
Beyond the preview
Go deeper on SBRX17.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SBRX17.